CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing
© 2022. The Author(s)..
PURPOSE: Accurate glioma classification affects patient management and is challenging on non- or low-enhancing gliomas. This study investigated the clinical value of different chemical exchange saturation transfer (CEST) metrics for glioma classification and assessed the diagnostic effect of the presence of abundant fluid in glioma subpopulations.
METHODS: Forty-five treatment-naïve glioma patients with known isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status received CEST MRI (B1rms = 2μT, Tsat = 3.5 s) at 3 T. Magnetization transfer ratio asymmetry and CEST metrics (amides: offset range 3-4 ppm, amines: 1.5-2.5 ppm, amide/amine ratio) were calculated with two models: 'asymmetry-based' (AB) and 'fluid-suppressed' (FS). The presence of T2/FLAIR mismatch was noted.
RESULTS: IDH-wild type had higher amide/amine ratio than IDH-mutant_1p/19qcodel (p < 0.022). Amide/amine ratio and amine levels differentiated IDH-wild type from IDH-mutant (p < 0.0045) and from IDH-mutant_1p/19qret (p < 0.021). IDH-mutant_1p/19qret had higher amides and amines than IDH-mutant_1p/19qcodel (p < 0.035). IDH-mutant_1p/19qret with AB/FS mismatch had higher amines than IDH-mutant_1p/19qret without AB/FS mismatch ( < 0.016). In IDH-mutant_1p/19qret, the presence of AB/FS mismatch was closely related to the presence of T2/FLAIR mismatch (p = 0.014).
CONCLUSIONS: CEST-derived biomarkers for amides, amines, and their ratio can help with histomolecular staging in gliomas without intense contrast enhancement. T2/FLAIR mismatch is reflected in the presence of AB/FS CEST mismatch. The AB/FS CEST mismatch identifies glioma subgroups that may have prognostic and clinical relevance.
| Errataetall: |
ErratumIn: Eur J Nucl Med Mol Imaging. 2022 Apr 12;:. - PMID 35412055 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:49 |
|---|---|
| Enthalten in: |
European journal of nuclear medicine and molecular imaging - 49(2022), 7 vom: 09. Juni, Seite 2377-2391 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mancini, Laura [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.05.2022 Date Revised 31.08.2022 published: Print-Electronic ErratumIn: Eur J Nucl Med Mol Imaging. 2022 Apr 12;:. - PMID 35412055 Citation Status MEDLINE |
|---|
| doi: |
10.1007/s00259-022-05676-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335645852 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335645852 | ||
| 003 | DE-627 | ||
| 005 | 20231225230325.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00259-022-05676-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335645852 | ||
| 035 | |a (NLM)35029738 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mancini, Laura |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CEST MRI provides amide/amine surrogate biomarkers for treatment-naïve glioma sub-typing |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.05.2022 | ||
| 500 | |a Date Revised 31.08.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Eur J Nucl Med Mol Imaging. 2022 Apr 12;:. - PMID 35412055 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022. The Author(s). | ||
| 520 | |a PURPOSE: Accurate glioma classification affects patient management and is challenging on non- or low-enhancing gliomas. This study investigated the clinical value of different chemical exchange saturation transfer (CEST) metrics for glioma classification and assessed the diagnostic effect of the presence of abundant fluid in glioma subpopulations | ||
| 520 | |a METHODS: Forty-five treatment-naïve glioma patients with known isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion status received CEST MRI (B1rms = 2μT, Tsat = 3.5 s) at 3 T. Magnetization transfer ratio asymmetry and CEST metrics (amides: offset range 3-4 ppm, amines: 1.5-2.5 ppm, amide/amine ratio) were calculated with two models: 'asymmetry-based' (AB) and 'fluid-suppressed' (FS). The presence of T2/FLAIR mismatch was noted | ||
| 520 | |a RESULTS: IDH-wild type had higher amide/amine ratio than IDH-mutant_1p/19qcodel (p < 0.022). Amide/amine ratio and amine levels differentiated IDH-wild type from IDH-mutant (p < 0.0045) and from IDH-mutant_1p/19qret (p < 0.021). IDH-mutant_1p/19qret had higher amides and amines than IDH-mutant_1p/19qcodel (p < 0.035). IDH-mutant_1p/19qret with AB/FS mismatch had higher amines than IDH-mutant_1p/19qret without AB/FS mismatch ( < 0.016). In IDH-mutant_1p/19qret, the presence of AB/FS mismatch was closely related to the presence of T2/FLAIR mismatch (p = 0.014) | ||
| 520 | |a CONCLUSIONS: CEST-derived biomarkers for amides, amines, and their ratio can help with histomolecular staging in gliomas without intense contrast enhancement. T2/FLAIR mismatch is reflected in the presence of AB/FS CEST mismatch. The AB/FS CEST mismatch identifies glioma subgroups that may have prognostic and clinical relevance | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a 1p/19q codeletion | |
| 650 | 4 | |a Chemical exchange saturation transfer | |
| 650 | 4 | |a Glioma risk stratification | |
| 650 | 4 | |a Isocitrate dehydrogenase | |
| 650 | 4 | |a Oligodendroglioma | |
| 650 | 7 | |a Amides |2 NLM | |
| 650 | 7 | |a Amines |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Isocitrate Dehydrogenase |2 NLM | |
| 650 | 7 | |a EC 1.1.1.41 |2 NLM | |
| 700 | 1 | |a Casagranda, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Gautier, Guillaume |e verfasserin |4 aut | |
| 700 | 1 | |a Peter, Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a Lopez, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Thorne, Lewis |e verfasserin |4 aut | |
| 700 | 1 | |a McEvoy, Andrew |e verfasserin |4 aut | |
| 700 | 1 | |a Miserocchi, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Samandouras, George |e verfasserin |4 aut | |
| 700 | 1 | |a Kitchen, Neil |e verfasserin |4 aut | |
| 700 | 1 | |a Brandner, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a De Vita, Enrico |e verfasserin |4 aut | |
| 700 | 1 | |a Torrealdea, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Rega, Marilena |e verfasserin |4 aut | |
| 700 | 1 | |a Schmitt, Benjamin |e verfasserin |4 aut | |
| 700 | 1 | |a Liebig, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Sanverdi, Eser |e verfasserin |4 aut | |
| 700 | 1 | |a Golay, Xavier |e verfasserin |4 aut | |
| 700 | 1 | |a Bisdas, Sotirios |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of nuclear medicine and molecular imaging |d 2002 |g 49(2022), 7 vom: 09. Juni, Seite 2377-2391 |w (DE-627)NLM116957360 |x 1619-7089 |7 nnns |
| 773 | 1 | 8 | |g volume:49 |g year:2022 |g number:7 |g day:09 |g month:06 |g pages:2377-2391 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s00259-022-05676-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 49 |j 2022 |e 7 |b 09 |c 06 |h 2377-2391 | ||